Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer opposes the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline lacks transparency and diverts the FDA's focus from its core mission of ensuring drug efficacy.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer opposes the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of drug pricing as a "national priority" undermine the FDA's role in ensuring drug efficacy and transparency.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer is urging the FDA to discontinue the CNPV Pilot Program. The commenter argues that the program prioritizes political interests over scientific scrutiny, lacks transparency, and poses safety risks to patients by significantly shortening the drug review timeline.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.

A patient and consumer is opposing the CNPV Pilot Program, arguing that it prioritizes political goals over scientific rigor and safety. The commenter expresses concern that the expedited review timeline and the inclusion of non-FDA priorities like drug pricing will undermine the agency's transparency and independence.